|
|
|
| Outsourced Pharma Capabilities Update: Nanoparticles (Aug. 18, 2026, 11:00 AM ET) | This session explores why nanoparticle programs succeed or stall. Experts examine how early formulation decisions—such as lipid composition, particle engineering, and process design—impact scalability, tech transfer, and commercialization. Learn how CDMO strategies influence risk, uncover hidden tradeoffs, and identify early signals of downstream challenges to improve development timelines and manufacturing outcomes for advanced nanoparticle therapeutics. Register here. |
|
|
|
|
|
| Patient Adherence With A Novel Dosage Form | Case Study | Adare Pharma Solutions | A sprinkle formulation helps patients with tremors or dysphagia take medication more easily, improving adherence, comfort, and care through a novel, FDA-approved oral granule format. |
|
|
|
|
By Louis Garguilo, Chief Editor, Outsourced Pharma | CDMO mergers and acquisitions and the addition of services has been a dominating trend in outsourcing; comprehensive offerings and scale are proclaimed indispensable to customers. Sufficient time has now elapsed so we can evaluate this era of more and those claims. Chief Editor Louis Garguilo looks into the evidence, and comes up with some interesting developments. | |
|
|
The CDMO Intelligence Report: Opportunities, Threats, And Market Signals | By GlobalData | Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities and Threats (CMOT) Report” to our readers. The report identifies CDMOs that might be impacted by key events affecting their clients, including company acquisitions, product acquisitions and licenses, product approvals, late clinical product terminations, and FDA rejections. |
|
|
INDUSTRY INSIGHTS CONTINUED |
|
|
|
|
|
|
|
|
|
|
|
|
|
OUTSOURCED PHARMA CAPABILITIES UPDATE |
|
|
|
CDMOs in biologics, cell and gene, and small molecule share their capabilities and available capabilities. See for yourself why this virtual event has become a wildly popular resource to identify options for your development and manufacturing needs. |
|
|
| Connect With Outsourced Pharma: |
|
|
|